{
  "trial_id": "NCT04637282",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Male and female participants between the ages of 5 and 18 years of age.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Has a diagnosis of 'classic' CLN3 disease as determined by age of symptom onset (i.e., 4 to 7 years) and genetic analysis for a defect in the CLN3 (battenin) transmembrane gene at study entry.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Participant must have a mild-to-moderate CLN3 disease documented by the UBDRS.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Participants are included with a Baseline UBDRS \u2264 15 for Physical Assessment.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Participant must be able to independently walk for a distance of at least 20 feet (6 meters).",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Participant must be able to tolerate swallowing oral medication or have a gastric/jejunostomy tube for drug administration.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Participants who are of childbearing potential (i.e., have begun menstruation) must have a negative serum pregnancy test at Baseline before receiving PLX-200.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Participants' parents/guardians must agree to comply in good faith with the conditions of the study, including attending all required baseline and follow-up assessments.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Participants' parents and legal guardians must sign the informed consent form, and participants will provide assent, depending on local regulations and developmental status.",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "Participant has asymptomatic CLN3 disease, defined as no evidence of neurological signs or symptoms attributed to CLN3 disease such as seizures, ataxia, language delay, or other developmental delays.",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "Participant has clinically documented generalized motor status epilepticus within 4 weeks of the Baseline visit (treatment may be postponed after discussion with the Medical Monitor until seizures are adequately controlled).",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He has mild Hoehn-Yahr Stage I disease and lives with his wife.",
  "_meta": {
    "topic_id": "75",
    "trial_id": "NCT04637282",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}